Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.

Cells
Sebastian SchollFlorian H Heidel

Abstract

Treatment of FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive acute myeloid leukemia (AML) remains a challenge despite the development of novel FLT3-directed tyrosine kinase inhibitors (TKI); the relapse rate is still high even after allogeneic stem cell transplantation. In the era of next-generation FLT3-inhibitors, such as midostaurin and gilteritinib, we still observe primary and secondary resistance to TKI both in monotherapy and in combination with chemotherapy. Moreover, remissions are frequently short-lived even in the presence of continuous treatment with next-generation FLT3 inhibitors. In this comprehensive review, we focus on molecular mechanisms underlying the development of resistance to relevant FLT3 inhibitors and elucidate how this knowledge might help to develop new concepts for improving the response to FLT3-inhibitors and reducing the development of resistance in AML. Tailored treatment approaches that address additional molecular targets beyond FLT3 could overcome resistance and facilitate molecular responses in AML.

References

Feb 5, 2004·Molecular Cell·James GriffithKumkum Saxena
Apr 16, 2005·Molecular and Cellular Biology·Dirk-E Schmidt-ArrasFrank-D Böhmer
Feb 1, 2006·The Journal of Experimental Medicine·Hanna S RadomskaDaniel G Tenen
Jul 28, 2006·British Journal of Haematology·Kyu-Tae KimDonald Small
Feb 22, 2007·Blood·Martin BornhäuserUNKNOWN AML SHG 96 study group
Jan 31, 2008·Journal of the National Cancer Institute·Weiguo ZhangMichael Andreeff
Jan 16, 2009·Blood·Frank BreitenbuecherThomas Fischer
Oct 27, 2009·Molecular Cell·Chunaram ChoudharyHubert Serve
Feb 1, 2009·Expert Review of Hematology·Amir T Fathi, Mark Levis
Jul 12, 2013·PloS One·Rama Krishna KanchaJustus Duyster
Aug 24, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sharyn D BakerHiroto Inaba

❮ Previous
Next ❯

Citations

Jun 4, 2021·Blood·J Cloos, G J Ossenkoppele
Jun 8, 2021·HemaSphere·Felicitas Thol, Michael Heuser

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.